Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by GameChangerBeton May 20, 2021 7:37am
140 Views
Post# 33236255

RE:RE:RE:What is the scenario

RE:RE:RE:What is the scenario
YukonJezza wrote:
GameChangerBet wrote:
Notthatbright wrote: should the shareholdres vote against amalgamation?


You certainly want to amalgamate. You want your shares to own the IP.
Any potential future aquiring event will likely require the IP, package deal.

In addition to that, you absolutely want senior management to own the same common shares you do, as opposed to owning shares in AH where they sit back and collect royalties that ATE would have owed them from future sales. Everyone is now on the same page.
What's good for the bosses, will be good for us shareholders.


so for the last 8 years they should have amalagamated so everyone is now on the same page. Your words pumper


Do you have any concept of how a business or corporation works?
They started out with a particular structure. 
At this point in time, given how far along they have come, they have come to the conclusion that it makes more sense to maintain everything under one company as opposed to having any part of it under a holding company or subsidiary.
There are a team of people. Yes there is a CEO who needs to sign off on all decisions, however CEO's rarely make those decisions on their own. They have business advisors, they have science advisors, advisors on financial structure.
Now that their product is getting closer to legitimacy, they see the opportunity in a diferrent way.

Perhaps Don Haut advised Dan that this amalgamation needs to happen in order for the company to be aquired in it's entirety.
I have no idea if that's the case, however it would at least make some sense. 

This repetitive rhetoric of "8 years ago". This is not the same company that it was 8 years ago. 
Of course they're going to make adjustments along the way as they deem necessary.

For the love of common sense, expand your thought process, just a little.
<< Previous
Bullboard Posts
Next >>